NCT05954312 2026-03-18
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Vividion Therapeutics, Inc.
Phase 1 Recruiting
Vividion Therapeutics, Inc.
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
UNICANCER
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)